| Q40845153 | 15-Deoxy-Δ(12,14)-prostaglandin J2 Induces Apoptosis and Upregulates SOCS3 in Human Thyroid Cancer Cells. |
| Q47572315 | A STAT3-dependent transcriptional circuitry inhibits cytotoxic gene expression in T cells |
| Q64997138 | A diet including xanthan gum triggers a pro-inflammatory response in Wistar rats inoculated with Walker 256 cells. |
| Q30841144 | A network-based method for mechanistic investigation of Shexiang Baoxin Pill's treatment of cardiovascular diseases. |
| Q37418671 | A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. |
| Q36973832 | A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells |
| Q37172697 | A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells |
| Q39078279 | A positive feedback loop between STAT3 and cyclooxygenase-2 gene may contribute to Helicobacter pylori-associated human gastric tumorigenesis |
| Q35022199 | A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-κB in tumors |
| Q35587194 | A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells |
| Q41201253 | AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells. |
| Q58062122 | Activated signal transducer and activator of transcription-3 (STAT3) is a poor regulator of tumour necrosis factor-alpha production by human monocytes |
| Q92155471 | Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity |
| Q38325370 | Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression |
| Q37275304 | Adoptive immunotherapy of cancer using CD4(+) T cells |
| Q44717067 | Alterations of oncogenes expression in NK cells in patients with cancer |
| Q36809767 | Altered macrophage differentiation and immune dysfunction in tumor development |
| Q38741291 | An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. |
| Q37830361 | Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy |
| Q36239694 | Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans |
| Q35501550 | Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. |
| Q33772651 | Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling |
| Q28068981 | Aptamers: A New Technological Platform in Cancer Immunotherapy |
| Q33578030 | Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM |
| Q41458660 | Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients. |
| Q38779010 | Autologous reconstitution of human cancer and immune system in vivo. |
| Q92736934 | Autophagy in breast cancer metastatic dormancy: Tumor suppressing or tumor promoting functions? |
| Q50056654 | B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors |
| Q34755398 | B cells promote tumor progression via STAT3 regulated-angiogenesis |
| Q50105604 | Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models |
| Q37280039 | Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells |
| Q28742177 | Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells |
| Q36925696 | Breast cancer vaccines: promise for the future or pipe dream? |
| Q41882583 | Btk regulates macrophage polarization in response to lipopolysaccharide. |
| Q37334492 | Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells |
| Q98735746 | C1EIP Functions as an Activator of ENO1 to Promote Chicken PGCs Formation via Inhibition of the Notch Signaling Pathway |
| Q36118086 | CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer |
| Q36595788 | CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation |
| Q36832883 | CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer |
| Q55243718 | CD8+ T cells mediate the antitumor activity of frankincense and myrrh in hepatocellular carcinoma. |
| Q34944413 | CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation |
| Q38203815 | CNS macrophages and peripheral myeloid cells in brain tumours |
| Q33808334 | CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells |
| Q41599729 | CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis |
| Q38576504 | Cancer and the Immune System: Basic Concepts and Targets for Intervention |
| Q24655415 | Cancer immunoediting from immune surveillance to immune escape |
| Q36605447 | Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity |
| Q26860058 | Cancer microenvironment, inflammation and cancer stem cells: A hypothesis for a paradigm change and new targets in cancer control |
| Q26769757 | Cancer stem cells and immunoresistance: clinical implications and solutions |
| Q37769017 | Cancer-associated myeloproliferation: old association, new therapeutic target |
| Q50901745 | Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy. |
| Q27860907 | Cancer-related inflammation |
| Q22242922 | Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability |
| Q42417570 | Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism |
| Q33567401 | Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation |
| Q38170150 | Cellular and molecular mechanisms in cancer immune escape: a comprehensive review |
| Q37970682 | Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment |
| Q28475010 | Chemical probes that competitively and selectively inhibit Stat3 activation |
| Q41830371 | Chemokine research moves on. |
| Q83169012 | Chemokines in health and disease |
| Q35928265 | Chronic inflammation in cancer development. |
| Q37709902 | Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. |
| Q58787284 | Clinicopathologic and prognostic significance of VEGF, JAK2 and STAT3 in patients with nasopharyngeal carcinoma |
| Q92377399 | Clinicopathological and Prognostic Role of STAT3/p-STAT3 in Breast Cancer Patients in China: A Meta-Analysis |
| Q39429955 | Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity |
| Q33950966 | Combined logical and data-driven models for linking signalling pathways to cellular response. |
| Q36407235 | Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas |
| Q26827618 | Control of Macrophage Dynamics as a Potential Therapeutic Approach for Clinical Disorders Involving Chronic Inflammation |
| Q36508931 | Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma |
| Q48125231 | Crocin Suppresses Constitutively Active STAT3 Through Induction of Protein Tyrosine Phosphatase SHP-1. |
| Q37822746 | Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity |
| Q36691086 | Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. |
| Q35740104 | Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. |
| Q37133450 | Cytokine signaling modules in inflammatory responses |
| Q42144694 | Cytomegalovirus and tumors: two players for one goal-immune escape |
| Q38716879 | Cytosolic DNA Promotes Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation by TANK-binding Kinase 1 (TBK1) to Restrain STAT3 Activity |
| Q28267996 | Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer |
| Q40501904 | Decline of miR-124 in myeloid cells promotes regulatory T-cell development in hepatitis C virus infection. |
| Q41865091 | Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models |
| Q39270204 | Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma |
| Q34997011 | Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function |
| Q34582889 | Dendritic cell subsets in health and disease. |
| Q38091116 | Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy |
| Q36436168 | Dendritic cell-based tumor vaccines and antigen presentation attenuators |
| Q34661797 | Dendritic cell-based vaccines: barriers and opportunities |
| Q35191027 | Density of Gr1-positive myeloid precursor cells, p-STAT3 expression and gene expression pattern in canine mammary cancer metastasis |
| Q35701322 | Differential Cytotoxicity but Augmented IFN-γ Secretion by NK Cells after Interaction with Monocytes from Humans, and Those from Wild Type and Myeloid-Specific COX-2 Knockout Mice |
| Q37726379 | Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. |
| Q38053983 | Diffuse large B cell lymphoma: molecular targeted therapy |
| Q35415906 | Dihydroxypentamethoxyflavone down-regulates constitutive and inducible signal transducers and activators of transcription-3 through the induction of tyrosine phosphatase SHP-1 |
| Q89474348 | Distinct effects of general anesthetics on lung metastasis mediated by IL-6/JAK/STAT3 pathway in mouse models |
| Q90181415 | Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas |
| Q41785517 | Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells. |
| Q37246466 | Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. |
| Q88301302 | Dysfunction of antigen processing and presentation by dendritic cells in cancer |
| Q41913268 | EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. |
| Q37456808 | Effects of notch signaling on regulation of myeloid cell differentiation in cancer |
| Q41863613 | Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. |
| Q41956511 | Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors |
| Q87179773 | Epithelial-mesenchymal transition: a new target in anticancer drug discovery |
| Q37619881 | Essential role of IL-10/STAT3 in chronic stress-induced immune suppression |
| Q36730400 | Essentials of Th17 cell commitment and plasticity |
| Q58801299 | Expansion and activation of monocytic-myeloid-derived suppressor cell via STAT3/arginase-I signaling in patients with ankylosing spondylitis |
| Q40761860 | Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals. |
| Q41215316 | Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma |
| Q34898306 | Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets |
| Q39523484 | Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). |
| Q36990588 | From cancer immunosurveillance to cancer immunotherapy |
| Q38287775 | Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment. |
| Q36547291 | G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers |
| Q36832717 | G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells. |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q34129168 | Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway |
| Q39196377 | Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. |
| Q34992518 | Glioma cancer stem cells induce immunosuppressive macrophages/microglia |
| Q24631473 | Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype |
| Q41475223 | Gut REG3γ-Associated Lactobacillus Induces Anti-inflammatory Macrophages to Maintain Adipose Tissue Homeostasis |
| Q46952190 | Gut-derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin-6/signal transducer and activator of transcription 3 activity |
| Q35016985 | HDAC inhibition and graft versus host disease |
| Q34261887 | HIV-1 gp120 activates the STAT3/interleukin-6 axis in primary human monocyte-derived dendritic cells |
| Q36809755 | Harnessing the immune system to treat cancer |
| Q37499246 | Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation |
| Q40686250 | Hepatitis C virus-induced myeloid-derived suppressor cells regulate T-cell differentiation and function via the signal transducer and activator of transcription 3 pathway |
| Q92104140 | Hepatocellular carcinoma: Mechanisms of progression and immunotherapy |
| Q38990675 | High-Intensity Focused Ultrasound- and Radiation Therapy-Induced Immuno-Modulation: Comparison and Potential Opportunities |
| Q34555169 | Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer |
| Q38898974 | Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) |
| Q41866168 | Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma |
| Q37287162 | How tumours escape mass destruction |
| Q33809268 | Hypoxia potentiates glioma-mediated immunosuppression |
| Q38719376 | IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay |
| Q34989745 | IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway |
| Q34690808 | IL-17 enhances tumor development in carcinogen-induced skin cancer |
| Q42139164 | IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo |
| Q36267150 | IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung |
| Q37658270 | IRE1α-XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling |
| Q39201613 | Icariside II induces apoptosis of melanoma cells through the downregulation of survival pathways |
| Q50351898 | Identification of Shared Molecular Signatures Indicate the Susceptibility of Endometriosis to Multiple Sclerosis. |
| Q38989773 | Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy |
| Q34723594 | Immune biomarkers of anti-EGFR monoclonal antibody therapy |
| Q38558749 | Immune deficiency vs. immune excess in inflammatory bowel diseases-STAT3 as a rheo-STAT of intestinal homeostasis |
| Q37435455 | Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas |
| Q38409605 | Immune modulatory nanoparticle therapeutics for intracerebral glioma. |
| Q34676437 | Immune therapeutic targeting of glioma cancer stem cells |
| Q27861048 | Immunity, Inflammation, and Cancer |
| Q39671902 | Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma |
| Q54918600 | Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer. |
| Q34480557 | Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? |
| Q87861147 | Immunotherapy for Head and Neck Squamous Cell Carcinoma |
| Q38736238 | Immunotherapy for head and neck cancer: the future of treatment? |
| Q33731552 | Immunotherapy in acute leukemia |
| Q36033384 | Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity |
| Q41075854 | Improvement of cancer immunotherapy by combining molecular targeted therapy. |
| Q37830362 | Improving cancer immunotherapy by targeting tumor-induced immune suppression |
| Q39800142 | In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses |
| Q42089413 | Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). |
| Q36974700 | Inflammation and lung carcinogenesis: applying findings in prevention and treatment. |
| Q28396089 | Inflammation and skeletal metastasis |
| Q33959754 | Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors |
| Q39036666 | Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. |
| Q37294261 | Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway |
| Q90468395 | Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma |
| Q34028436 | Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model |
| Q37744890 | Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis |
| Q24641894 | Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein |
| Q34117204 | Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. |
| Q38989227 | Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1. |
| Q34055968 | Innate immune regulation by STAT-mediated transcriptional mechanisms. |
| Q38162129 | Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer |
| Q37259195 | Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation |
| Q84365414 | Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3 |
| Q37986022 | Intersecting pathways in inflammation and cancer: Hepatocellular carcinoma as a paradigm |
| Q37093219 | Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape |
| Q34393758 | Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses |
| Q38369000 | Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer |
| Q92418418 | JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors |
| Q47294990 | JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance |
| Q50332327 | Knockdown of BC200 RNA expression reduces cell migration and invasion by destabilizing mRNA for calcium-binding protein S100A11. |
| Q37709119 | Laricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3 |
| Q37535365 | Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. |
| Q37429706 | Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. |
| Q36924962 | Lineage-specific transcription factors in unexpected places. |
| Q50017138 | LncRNA RNCR3 promotes Chop expression by sponging miR-185-5p during MDSC differentiation |
| Q35086418 | Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance |
| Q34198365 | Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study |
| Q30465410 | M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer |
| Q58806291 | MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells |
| Q29614349 | Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm |
| Q37945300 | Macrophages in cancer and infectious diseases: the 'good' and the 'bad'. |
| Q41113415 | Macrophages, Inflammation, and Lung Cancer |
| Q37695149 | Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. |
| Q33707270 | Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells |
| Q27003907 | Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues |
| Q36490750 | Mechanisms of immune evasion by tumors |
| Q33604925 | Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells |
| Q27309991 | Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells |
| Q39182404 | Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation |
| Q40155875 | Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma |
| Q42969286 | MicroRNAs as novel immunotherapeutics |
| Q26747339 | MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma |
| Q36882759 | Modulation of tumorigenesis by the pro-inflammatory microRNA miR-301a in mouse models of lung cancer and colorectal cancer |
| Q38918609 | Molecular mechanisms involved in dendritic cell dysfunction in cancer |
| Q37729131 | Molecular pathways and targets in cancer-related inflammation |
| Q52726024 | Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer. |
| Q36733992 | Multidisciplinary frontiers in breast cancer management: a surgeon's perspective |
| Q36343400 | Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. |
| Q50420763 | Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition. |
| Q35799053 | Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice |
| Q38953721 | Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities |
| Q51684916 | Myeloid cells in tumour-immune interactions. |
| Q34746658 | Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer |
| Q28082461 | Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy |
| Q30422587 | Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species |
| Q27000087 | Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship |
| Q28131637 | Myeloid-derived suppressor cells as regulators of the immune system |
| Q38578686 | Myeloid-derived suppressor cells in B cell malignancies. |
| Q24641811 | Myeloid-derived suppressor cells: linking inflammation and cancer |
| Q37019136 | Myeloid-derived suppressor cells: natural regulators for transplant tolerance |
| Q37070694 | Myeloid-specific expression of Api6/AIM/Sp alpha induces systemic inflammation and adenocarcinoma in the lung |
| Q36698670 | Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. |
| Q37457873 | NF-kappaB and STAT3 signaling in glioma: targets for future therapies |
| Q38088677 | NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer |
| Q90383852 | Nanoparticles Targeting STATs in Cancer Therapy |
| Q33575787 | Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes |
| Q90732970 | Neutrophil Heterogeneity in Cancer: From Biology to Therapies |
| Q35274726 | Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model |
| Q90811847 | Nouvelles stratégies innovantes en immunothérapie |
| Q38179031 | Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature. |
| Q55030171 | Novel quinazoline-based sulfonamide derivative (3D) induces apoptosis in colorectal cancer by inhibiting JAK2-STAT3 pathway. |
| Q58722853 | Nucleus, Mitochondrion, or Reticulum? STAT3 à La Carte |
| Q37698792 | Nutritional control of IL-23/Th17-mediated autoimmune disease through HO-1/STAT3 activation |
| Q35848756 | Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells |
| Q36543791 | Order, disorder, death: lessons from a superorganism |
| Q41910192 | Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). |
| Q90697887 | Overview of the STAT-3 signaling pathway in cancer and the development of specific inhibitors |
| Q97883099 | P-STAT3 Inhibition Activates Endoplasmic Reticulum Stress-Induced Splenocyte Apoptosis in Chronic Stress |
| Q38047052 | PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells |
| Q47347202 | PSMB5 plays a dual role in cancer development and immunosuppression |
| Q41721009 | Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration. |
| Q24312920 | Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors |
| Q37693733 | Personalized dendritic cell-based tumor immunotherapy |
| Q28079046 | Phenotype, development, and biological function of myeloid-derived suppressor cells |
| Q41317820 | Pivotal regulators of tissue homeostasis and cancer: macrophages |
| Q64118067 | Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model |
| Q34552079 | Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer |
| Q36883848 | Promising systemic immunotherapies in head and neck squamous cell carcinoma |
| Q37866632 | RNAi-based therapeutic strategies for metabolic disease |
| Q92306377 | Radioimmunotherapy for the treatment of head and neck cancer |
| Q81413480 | Recurrence in head and neck squamous cell carcinoma. Editorial |
| Q35626914 | Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. |
| Q26752551 | Regulation of Natural Killer Cell Function by STAT3 |
| Q37088657 | Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance |
| Q37982182 | Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells |
| Q37169987 | Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment |
| Q41492330 | Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer |
| Q37062216 | Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions |
| Q33736664 | Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy |
| Q38262473 | Revisiting STAT3 signalling in cancer: new and unexpected biological functions |
| Q38245925 | Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme |
| Q35147988 | Role of Rip2 in development of tumor-infiltrating MDSCs and bladder cancer metastasis |
| Q36086059 | Role of STAT3 in lung cancer |
| Q37529686 | Role of STAT3 in regulatory T lymphocyte plasticity during acute graft-vs.-host-disease |
| Q38776978 | Role of STAT3 pathway in genitourinary tumors. |
| Q36797504 | Role of Stat3 in suppressing anti-tumor immunity |
| Q58862468 | Role of Tumor-Associated Macrophages (TAM) in Cancer Related Inflammation |
| Q37710885 | Role of estrogen in hepatocellular carcinoma: is inflammation the key? |
| Q37606102 | Role of immune cells in pancreatic cancer from bench to clinical application: An updated review |
| Q36370860 | Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells |
| Q37596178 | Role of the tumor microenvironment in the pathogenesis of gastric carcinoma |
| Q34821218 | S100B attenuates microglia activation in gliomas: possible role of STAT3 pathway |
| Q30514214 | S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. |
| Q80100759 | SRC and STAT pathways |
| Q38116768 | STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention |
| Q38671957 | STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications |
| Q37315492 | STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis |
| Q47422451 | STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs. |
| Q58594424 | STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers |
| Q92704401 | STAT3 Inhibits CD103+ cDC1 Vaccine Efficacy in Murine Breast Cancer |
| Q35015488 | STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo |
| Q38205362 | STAT3 Target Genes Relevant to Human Cancers |
| Q34089708 | STAT3 activation in monocytes accelerates liver cancer progression |
| Q38140901 | STAT3 activation: A key factor in tumor immunoescape |
| Q36570495 | STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. |
| Q59336980 | STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial |
| Q52317592 | STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. |
| Q37029162 | STAT3 as a target for inducing apoptosis in solid and hematological tumors |
| Q35925086 | STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis. |
| Q89157989 | STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity |
| Q37162367 | STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon. |
| Q36395001 | STAT3 in immune responses and inflammatory bowel diseases |
| Q91211189 | STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells |
| Q34900634 | STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma |
| Q47806027 | STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. |
| Q36733391 | STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients |
| Q30409357 | STAT3 regulates uterine epithelial remodeling and epithelial-stromal crosstalk during implantation |
| Q34139886 | STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model |
| Q39393385 | STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy. |
| Q38396909 | STAT3 the oncogene - still eluding therapy? |
| Q93079065 | STAT3, a Master Regulator of Anti-Tumor Immune Response |
| Q36843729 | STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells |
| Q34936215 | STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. |
| Q36481079 | STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance |
| Q37762206 | STAT3: a target to enhance antitumor immune response |
| Q37429669 | STAT3: the "Achilles" heel for AML? |
| Q39114281 | STATs in NK-Cells: The Good, the Bad, and the Ugly |
| Q29547203 | STATs in cancer inflammation and immunity: a leading role for STAT3 |
| Q90731745 | Sanguinarine exhibits potent efficacy against cervical cancer cells through inhibiting the STAT3 pathway in vitro and in vivo |
| Q50915651 | Screening of Stat3 inhibitory effects of Korean herbal medicines in the A549 human lung cancer cell line. |
| Q24318448 | Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes |
| Q36229419 | Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program |
| Q38231265 | Serotonin modulation of macrophage polarization: inflammation and beyond |
| Q36755491 | Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia |
| Q37869903 | Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy |
| Q35235724 | Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis |
| Q38925157 | Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment |
| Q34940989 | Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target |
| Q28080262 | Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy |
| Q37417836 | Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells |
| Q38939956 | Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer |
| Q37174303 | Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas |
| Q36492439 | Signal transduction of inflammatory cytokines and tumor development |
| Q26783748 | Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages |
| Q42962555 | Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype |
| Q36627430 | Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. |
| Q37327668 | Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model. |
| Q37474510 | Stat3 and the inflammation/acute phase response in involution and breast cancer |
| Q39869527 | Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. |
| Q38810148 | Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity |
| Q28385532 | Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice |
| Q37972656 | Stat3: linking inflammation to (gastrointestinal) tumourigenesis |
| Q33921803 | Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? |
| Q64955585 | Stromal Infiltration of Tumor-Associated Macrophages Conferring Poor Prognosis of Patients with Basal-Like Breast Carcinoma. |
| Q55637644 | Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development. |
| Q50063665 | Structurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference |
| Q37147482 | Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells |
| Q36033134 | Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. |
| Q39994717 | Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. |
| Q52625023 | T-Cell Dysfunction in Glioblastoma: Applying a New Framework. |
| Q47575245 | TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs |
| Q34204722 | TLR9 is critical for glioma stem cell maintenance and targeting |
| Q37567832 | TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy |
| Q34320769 | TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo |
| Q29619243 | Taking dendritic cells into medicine |
| Q39399239 | Taming the immune system through transfusion in oncology patients |
| Q35374753 | Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth |
| Q37496791 | Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma |
| Q34763617 | Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles |
| Q47337796 | Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors |
| Q34473451 | Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. |
| Q82824786 | Targeting STAT3 in cancer: how successful are we? |
| Q37012605 | Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma |
| Q34681856 | Targeting Stat3 in the Myeloid Compartment Drastically Improves the In vivo Antitumor Functions of Adoptively Transferred T Cells |
| Q90687457 | Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer |
| Q38110540 | Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. |
| Q33786852 | Targeting Tumor Microenvironment: Effects of Chinese Herbal Formulae on Macrophage-Mediated Lung Cancer in Mice. |
| Q26746972 | Targeting microRNAs as key modulators of tumor immune response |
| Q50191433 | Targeting the IL-6/JAK/STAT3 signalling axis in cancer |
| Q27015876 | Targeting the innate immune system as immunotherapy for acute myeloid leukemia |
| Q34550440 | Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. |
| Q26825658 | Targeting the tumor microenvironment: JAK-STAT3 signaling |
| Q60909038 | The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease |
| Q92307792 | The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective |
| Q36945956 | The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis |
| Q36659528 | The Metabolic Prospective and Redox Regulation of Macrophage Polarization |
| Q37475929 | The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients |
| Q26778930 | The Role of the Transcriptional Regulation of Stromal Cells in Chronic Inflammation |
| Q38687571 | The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations |
| Q28538542 | The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model |
| Q37959968 | The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance |
| Q92462353 | The diverse mechanisms and anticancer potential of naphthoquinones |
| Q35987091 | The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival |
| Q39242855 | The immunological function of GABAergic system |
| Q37020840 | The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. |
| Q41481421 | The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages |
| Q33660069 | The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. |
| Q37849666 | The mechanisms of cancer immunoescape and development of overcoming strategies |
| Q36972016 | The metastasis-promoting roles of tumor-associated immune cells |
| Q38008966 | The molecular profile of microglia under the influence of glioma |
| Q37109549 | The multifaceted role of autophagy in tumor evasion from immune surveillance |
| Q38543552 | The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. |
| Q49990319 | The role of STAT3 in leading the crosstalk between human cancers and the immune system |
| Q38363102 | The role of STAT3 in tumor-mediated immune suppression |
| Q37994234 | The role of natural killer cells in immunity against multiple myeloma |
| Q26825678 | The role of obesity in gastrointestinal cancer: evidence and opinion |
| Q34546566 | The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression |
| Q37452411 | The role of tregs in glioma-mediated immunosuppression: potential target for intervention. |
| Q49684254 | The roles of CSFs on the functional polarization of tumor-associated macrophages |
| Q55465352 | The roles of signal transducer and activator of transcription 3 in tumor metastasis |
| Q42366665 | The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. |
| Q39521993 | The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies |
| Q42333838 | The tumor microenvironment disarms CD8+ T lymphocyte function via a miR-26a-EZH2 axis |
| Q64054927 | Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer |
| Q33684732 | Therapeutic modulators of STAT signalling for human diseases |
| Q38478878 | Therapeutic potential and challenges of natural killer cells in treatment of solid tumors |
| Q37089543 | Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin |
| Q90712078 | Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map |
| Q36759434 | Tissue-resident dendritic cells and diseases involving dendritic cell malfunction |
| Q33978723 | Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation. |
| Q42940654 | Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy |
| Q33917198 | Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. |
| Q33822831 | Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance |
| Q93006532 | Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer |
| Q38606460 | Tumor Microenvironment as a New Target for Tumor Immunotherapy of Polysaccharides |
| Q37598949 | Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses |
| Q30433292 | Tumor masses support naive T cell infiltration, activation, and differentiation into effectors |
| Q41062315 | Tumor-associated macrophages in glioma: friend or foe? |
| Q57470563 | Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8 |
| Q33662759 | Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance |
| Q33763653 | Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. |
| Q24648032 | Tumor-specific Th17-polarized cells eradicate large established melanoma |
| Q38109656 | Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers. |
| Q37191655 | miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma |
| Q35157437 | miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression. |
| Q98778652 | miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells |
| Q38307450 | miR-34a expands myeloid-derived suppressor cells via apoptosis inhibition |
| Q36434375 | p38 Mitogen-activated protein kinase/signal transducer and activator of transcription-3 pathway signaling regulates expression of inhibitory molecules in T cells activated by HIV-1-exposed dendritic cells |
| Q58665562 | siRNA delivery not Toll-free |
| Q37420546 | yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. |
| Q35015164 | ω3-PUFAs exert anti-inflammatory activity in visceral adipocytes from colorectal cancer patients |